Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 97

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 97
---
against litigation is costly and time consuming, and could divert our management’s attention and our resources. Furthermore, during
the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings
or developments, which could have a negative effect on the market price of our Depositary Shares.

| 48 |

Shareholder ownership interests in the Company may be diluted as a result of, among other things, future financings and/or additional acquisitions, and may have a material negative effect on the market price of our securities.

We may seek to raise additional
funds from time to time in public or private issuances of equity and such financings may take place in the near future or over the longer
term. Sales of our securities offered through future equity offerings may result in substantial dilution to the interests of our current
shareholders. The sale of a substantial number of securities to investors, or anticipation of such sales, could make it more difficult
for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

We may also issue Ordinary
Shares (and Depositary Shares underlying such Ordinary Shares) or other securities convertible into Ordinary Shares from time to time
for future acquisitions, including acquisitions of licenses. The issuance of the securities underlying these instruments, or perception
that issuance may occur, will have a dilutive impact on other shareholders and could have a material negative effect on the market price
of our Depositary Shares.

If equity research analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our
securities will depend in part on the research and reports that equity research analysts publish about us or our business. If no or few equity research analysts cover our Company, the trading price for oursecurities would be negatively impacted. We do not have any control over the analysts or the content and opinions included in their reports. The price of oursecurities could decline if one or more equity research analysts downgrade oursecurities
or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for oursecurities could decrease, which in turn could cause the trading price or trading volume of oursecurities to decline.

The rights of holders of Depositary Shares are not the same as the rights of holders of Ordinary Shares.

We are a public limited company
incorpor